Bioequivalency Study of Zidovudine Under Fasting Conditions
Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg
tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fasting conditions using a
single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.